Propranolol and metoprolol are both beta-blockers prescribed for overlapping conditions, but they differ in one fundamental way that shapes almost every practical distinction between them: propranolol blocks beta-adrenergic receptors broadly across the body, while metoprolol preferentially targets the beta-1 receptors concentrated in the heart. That single difference in selectivity ripples outward into which drug works better for a given condition, which side effects you’re more likely to experience, and which situations make one a clearly better choice than the other.
What Beta-1 Selectivity Actually Means for You
Beta-adrenergic receptors come in two main subtypes relevant here. Beta-1 receptors are found primarily in heart tissue, where they regulate heart rate and the force of contractions. Beta-2 receptors sit in the airways, blood vessels, and other tissues, where they help keep bronchial passages open and blood flowing to the extremities. Metoprolol preferentially blocks beta-1 receptors, earning it the label “cardioselective.”1PubMed. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors Propranolol blocks both beta-1 and beta-2 receptors without significant preference for either.
This matters because when you block beta-2 receptors in the lungs, you risk narrowing the airways. When you block them in peripheral blood vessels, you can reduce blood flow to the fingers and toes. Propranolol does both of these things more than metoprolol does, which is why metoprolol tends to be the safer pick for people with respiratory issues or circulation problems. But propranolol’s broader blockade also gives it therapeutic advantages in conditions where blocking beta-2 receptors is part of the point.
Controlling Blood Pressure and Heart Rate
For straightforward hypertension, propranolol and metoprolol are close to interchangeable in effectiveness. Head-to-head trials dating back decades have consistently found no meaningful difference between the two in lowering blood pressure. A double-blind crossover study in hypertensive patients found no significant differences for blood pressure, heart rate, or body weight between the drugs.2PubMed. Comparison between metoprolol and propranolol as antihypertensive agents. A double-blind cross-over study. A separate three-way comparison of propranolol, metoprolol, and labetalol found little difference between them in blood pressure reduction, though both propranolol and metoprolol were better at lowering heart rate than labetalol.3PubMed. Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension
Another comparative trial found that blood pressure reductions plateaued at 160 mg daily for propranolol and 100 mg daily for metoprolol, with no further drop at higher doses of either drug.4Australian and New Zealand Journal of Medicine. A Comparison of Metoprolol and Propranolol on Blood Pressure and Respiratory Function in Patients with Hypertension So if blood pressure control is the sole concern, neither drug has a clear edge. The choice between them usually comes down to side-effect profiles and coexisting conditions.
Asthma and Breathing Problems
This is where the selectivity difference matters most acutely. Because propranolol blocks beta-2 receptors in the airways, it can trigger bronchospasm in people with asthma or chronic obstructive pulmonary disease. Metoprolol’s relative sparing of beta-2 receptors makes it the preferred beta-blocker when one is needed in someone with reactive airway disease.
That said, “preferred” does not mean “safe.” A network meta-analysis of randomized trials found that in patients with a baseline history of asthma, both oral propranolol and oral metoprolol were associated with significantly more asthma attacks than placebo. Propranolol carried roughly a threefold increased risk while metoprolol carried about a threefold risk as well, though propranolol’s point estimate was slightly higher. Intravenous propranolol was far worse, associated with about a tenfold increased risk.5PubMed Central. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials The practical takeaway: if you have asthma and genuinely need a beta-blocker, metoprolol is the less risky option, but your doctor will still monitor you carefully. Neither drug is benign for asthmatic patients.
Cold Hands and Peripheral Circulation
One of the most common complaints people have about beta-blockers is cold fingers and toes. Propranolol is substantially worse than metoprolol in this regard. In a study measuring skin temperature in healthy subjects, propranolol caused an average drop in mean skin temperature of about 1.3°C within 90 minutes of a single dose, while metoprolol caused a negligible drop of about 0.15°C. Propranolol also reduced skin blood flow and resting muscle blood flow, whereas metoprolol did not significantly affect either.6PubMed Central. Effects of propranolol and metoprolol on the peripheral circulation
This happens because beta-2 receptors in peripheral blood vessels normally help those vessels relax and dilate. Propranolol blocks that signal, allowing vasoconstriction to go unopposed. If you already have Raynaud’s phenomenon or poor circulation in your extremities, propranolol can make it noticeably worse. Metoprolol is a better fit for those patients.
Sleep, Dreams, and Brain Effects
Both drugs cross the blood-brain barrier, and both can cause central nervous system side effects including vivid dreams, sleep disturbances, and occasionally mood changes. These effects are tied to how easily a drug enters brain tissue, which depends largely on its lipophilicity. Propranolol is highly lipophilic, meaning it dissolves readily in fat and crosses into the brain easily. Metoprolol is moderately lipophilic, so it reaches the brain too, just not quite as readily.7PubMed Central. Metoprolol-Associated Central Nervous System Complications
In practice, both drugs are reported to cause vivid or bizarre dreams, and neither is cleanly free of CNS side effects. A review of beta-blocker CNS complications noted that the risk correlates with lipophilicity, and that the most commonly reported symptoms include psychiatric disturbances, vivid dreams, sleep disruption, delirium, psychosis, and visual hallucinations. These are rare at standard doses, but if you experience disturbing dreams or mood changes on one of these drugs, switching to a more hydrophilic beta-blocker like atenolol is sometimes the solution. Switching between propranolol and metoprolol may not help much, since both penetrate the brain to a meaningful degree.
Thyroid Storm and Hyperthyroidism
This is one of the clearest situations where propranolol has a specific advantage over metoprolol. In hyperthyroidism, excess thyroid hormone drives the heart to beat faster and harder, and beta-blockers are a mainstay for controlling those cardiovascular symptoms. Both propranolol and metoprolol will slow the heart rate. But propranolol does something extra: it inhibits the peripheral conversion of T4, the storage form of thyroid hormone, into T3, the more active form. This gives propranolol a dual benefit, controlling symptoms at the heart while also reducing the circulating level of the most potent thyroid hormone.8PubMed Central. Benefit and Preference of Propranolol Over Metoprolol in Thyrotoxicosis-Induced Atrial Fibrillation: A Case Report and Review of Literature
In thyroid storm, a life-threatening extreme of hyperthyroidism, guidelines from the American Thyroid Association and the European Thyroid Association recommend propranolol specifically, typically at doses of 60 to 80 mg every four hours.9PubMed Central. Approach to the Patient with Thyroid Storm Metoprolol can still control heart rate in thyroid storm, but it lacks the T4-to-T3 conversion benefit that makes propranolol the first choice.
Migraine Prevention
Both propranolol and metoprolol are used for migraine prophylaxis, and both have evidence supporting their effectiveness. A double-blind study comparing the two drugs for prevention of both classical and common migraine found no differences in efficacy between them. Both reduced migraine symptoms compared to a baseline run-in period and were generally well tolerated.10PubMed. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study
Propranolol has been studied more extensively for migraine and has a longer track record in clinical use for this purpose. It was one of the first beta-blockers used for migraine prevention, and many guidelines list it as a first-line agent. Metoprolol has strong evidence too, and some patients tolerate it better because of the reduced peripheral side effects. If you’re trying a beta-blocker for migraines and one causes intolerable cold extremities or fatigue, the other is a reasonable alternative without sacrificing much migraine protection.
Liver Disease and Portal Hypertension
Propranolol occupies a unique role in managing the complications of cirrhosis that metoprolol does not share. In advanced liver disease, pressure builds up in the portal vein system, increasing the risk of life-threatening variceal bleeding. Propranolol has been shown to significantly reduce hepatic venous pressure gradient by roughly 21%, along with reductions in portal venous flow of about 25%.11PubMed Central. Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective Study
The reason propranolol works here while metoprolol generally does not is again the selectivity issue, but from the opposite direction. Reducing portal pressure requires blocking both beta-1 receptors in the heart, which reduces cardiac output, and beta-2 receptors in the splanchnic (gut) blood vessels, which reduces blood flow into the portal system. A beta-1 selective drug like metoprolol addresses only half the equation. Propranolol, along with the newer nonselective beta-blocker carvedilol, is the standard of care for variceal bleeding prevention in cirrhosis.
Infantile Hemangiomas
One of propranolol’s more unexpected roles is in treating infantile hemangiomas, the bright red vascular birthmarks that appear in some newborns. The discovery was accidental: a child being treated with propranolol for a heart condition happened to have a hemangioma that shrank dramatically. Since then, oral propranolol has become the first-line medication for infantile hemangiomas that require treatment.12PubMed Central. Propranolol in the Treatment of Infantile Hemangiomas The mechanisms appear to involve multiple pathways, including constriction of blood vessels feeding the hemangioma and suppression of signals that promote new blood vessel growth.13PubMed Central. Mechanisms of propranolol action in infantile hemangioma
Metoprolol has not established a comparable role here. The anti-angiogenic effects appear to require nonselective beta-blockade, which is why propranolol dominates this niche entirely.
What Happens When You Stop
Abrupt withdrawal from either beta-blocker can cause rebound symptoms, but the pattern differs between the two drugs. Stopping a beta-blocker suddenly after regular use can lead to a spike in adrenergic activity because the body has upregulated its receptors during treatment. This can manifest as rebound hypertension, rapid heart rate, headache, palpitations, and tremor.14JAMA Internal Medicine. Rebound Hypertension Following Abrupt Cessation of Clonidine and Metoprolol: Treatment With Labetalol
A study comparing withdrawal from propranolol, metoprolol, and pindolol found that both propranolol and metoprolol caused withdrawal phenomena, while pindolol did not. The patterns were somewhat different: after metoprolol withdrawal, heart rate rebounded significantly above baseline in all patients studied, while after propranolol withdrawal, blood pressure overshot baseline in most patients. Withdrawal symptoms such as headache, palpitations, and tremor occurred in about two-thirds of patients stopping propranolol and roughly a third of those stopping metoprolol.15American Heart Journal. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol The bottom line is that neither drug should be stopped abruptly. A gradual taper over one to two weeks is standard practice for both.
Blood Sugar and Diabetes
A common concern with beta-blockers in people with diabetes is that they can mask the symptoms of low blood sugar, particularly tremor and rapid heart rate, making hypoglycemia harder to recognize. There’s also the question of whether they slow the body’s recovery from a low blood sugar episode. A study in patients with insulin-dependent diabetes found that both propranolol at 80 mg and metoprolol at 100 mg impaired recovery from insulin-induced hypoglycemia. The researchers concluded that at those doses, metoprolol was not safer than propranolol in this regard.16Diabetes Care. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus
The theoretical advantage of metoprolol is that because it spares beta-2 receptors (which are involved in stimulating glucose release from the liver), it should interfere less with hypoglycemia recovery. At low doses, that theoretical advantage may hold, but the study above shows that at commonly prescribed doses it does not reliably translate into a practical difference. People with diabetes on either drug should be counseled to watch for subtler signs of low blood sugar, such as sweating, which is not masked by beta-blockade.
Metoprolol Tartrate Versus Metoprolol Succinate
If your doctor prescribes metoprolol, you may get one of two formulations, and the distinction matters. Metoprolol tartrate is an immediate-release tablet typically dosed twice daily. Metoprolol succinate is a controlled-release formulation taken once daily. A pharmacokinetic study comparing the two found that the controlled-release form produced more stable drug levels throughout the day, with a lower peak concentration and a higher trough concentration at the end of the dosing interval compared to conventional tablets.17PubMed. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets
This steadier drug level means fewer peaks and valleys in heart rate and blood pressure control over the course of a day. Metoprolol succinate (often sold as Toprol-XL) is the version used in major heart failure trials and is generally the preferred formulation for heart failure management. Metoprolol tartrate (often sold as Lopressor) is commonly used for hypertension and acute heart rate control. They are not interchangeable milligram-for-milligram because of differences in how the drug is released and absorbed. If a pharmacy switches you from one to the other without adjusting the dose or frequency, ask your doctor whether the change is appropriate.
How Propranolol Became the First
Propranolol holds a notable place in the history of pharmacology. Developed by the British scientist Sir James Black in the early 1960s, it was the first clinically successful beta-blocker and was initially intended to treat angina pectoris.18PubMed Central. Propranolol: A 50-Year Historical Perspective Black’s work on propranolol earned him the Nobel Prize in Physiology or Medicine in 1988, and the drug’s invention has been described as one of the most important contributions to clinical medicine of the twentieth century.19PubMed Central. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology.
Metoprolol came along about a decade later, developed specifically to reduce the lung and peripheral side effects of nonselective beta-blockers. The differences between the pharmacokinetic properties of various beta-blockers, including their gastrointestinal absorption, first-pass metabolism in the liver, lipid solubility, and protein binding, are what allow clinicians to match a specific beta-blocker to a specific patient’s needs. Both drugs are metabolized primarily by the liver, but the rate of that metabolism varies substantially between individuals due to genetic differences in the CYP2D6 enzyme. About 5 to 10 percent of people of European descent are poor metabolizers of CYP2D6, meaning they break down both propranolol and metoprolol more slowly and may experience stronger effects at standard doses. If you seem unusually sensitive to either drug, slow metabolism is one possible explanation worth discussing with your prescriber.